Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression.
These results identify the PD-L1-driven immunosuppressive microenvironment as a key mediator of sotorasib resistance and propose PD-L1i as a synergistic strategy to overcome resistance, which warrants clinical exploration of sequential or combinatorial regimens.
Authors
- W. Cui
- Lina Jia
- Sihong Chen
- Linlin Wang (ORCID: https://orcid.org/0000-0002-7014-2149)
- Xiaohui Zhang (ORCID: https://orcid.org/0000-0003-0245-6792)
- Shougeng Liu
- Yingxi Zhao
- Simeng Wang (ORCID: https://orcid.org/0009-0000-2211-4322)
- Rao Fu
- Yuan Yang
- Weiming Yang
- Minmin Gao
- Mingze Qin
- Yiting Jiang
- Yudong Fu
Institutions
- Shenyang Pharmaceutical University (CN)
- China Medical University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1136/jitc-2025-012886
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00